Pod Insights Pharmacy Podcast Network Peddling a Fantasy: How Drugmakers are Misleading State Lawmakers| Essential: Pharmacy Compounding Podcast APC About this episode In this edition of Essential, we look at two major issues facing pharmacy compounding. First is a state-by-state effort by pharma companies to pass laws restricting compounding, and second is a cryptic statement from the FDA about possible limitations on compounding with GLP-1 ingredients. They’re both Very Big Deals for pharmacists across the country. LinksFDA statement on GLP-1 drugs: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs… and APC’s response: https://a4pc.org/news/apc-responds-to-fdas-glp-1-statement Stay up to date on our state Compounding Defense Initiative: compounding.com Join APC today: https://a4pc.org/membership Find us on social:LinkedIn: https://www.linkedin.com/company/a4pcrx/Facebook: https://www.facebook.com/a4pcrx/Instagram: https://www.instagram.com/a4pcrx/
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the pharmacy podcast network.
0:25 Speaker 01 Welcome back to Essential, the pharmacy compounding podcast with the latest news and analysis from you know who, the Alliance for Pharmacy Compounding, the voice for compounding pharmacy. I'm your host, Andrew Cantor, and today we've got something a little different. There are two big stories in the world of pharmacy compounding going on right now, and they're both important enough that we want to do kind of a double deep dive.
0:55 Speaker 01 The first is a broad effort on the part of a couple of big drug makers to get laws passed that make compounding a lot more difficult, and it is a broad effort. We'll get to that in a sec. The other is a public statement by the FDA on February 6th that the agency is looking at restricting semaglutide and terzepatide as active pharmaceutical ingredients. The statement was kind of cryptic. It wasn't like the agency was announcing a new policy or anything. It was just kind of thinking out loud. So everyone's guessing what might happen next. But before we get to that, let's go back to talking about what's going on in the states.
1:39 Speaker 01 When I said pharma companies were making a broad effort to restrict compounding, I mean they've literally authored legislation to do that, to limit compounding, and they've managed to get it introduced in about 10 states. To talk about all this and what it means, my guest is APC's CEO, Scott Brunner, who is obviously chin deep in all these issues. Welcome, Scott.
2:03 Speaker 02 It's actually deeper than that, Andrew. I'm pretty short, so my chin's not that tall, but thanks, I'm glad to be here.
2:09 Speaker 01 So rather than go through every state, since all these bills are pretty similar, let's talk in general terms. What is the gist of these bills that the pharma companies are introducing? And why are the companies pushing for them?
2:25 Speaker 02 Well, it's a coordinated effort. Across the country, Eli Lilly and Novo Nordisk are pitching legislators on a neat scary story. They're saying that licensed compounding pharmacies are some sort of shadow supply chain, that compounded GLP-1s are inherently suspect, and that these sweeping new state level restrictions framed as patient safety or anti-counterfeiting measures are the only possible responsible response. And yet, that story is a fantasy.
3:04 Speaker 02 And unfortunately, in the nine or 10 states, too many lawmakers are acting on them without checking the facts. We know that drug makers, since last summer, end of last summer, drug makers had been shopping legislation with legislators in various states. We had received copies of drafts. And then shortly after the first of the year, it's legislative session season across the country, and bills began to be introduced. The interesting thing about the legislation is that they have been pitched to legislators as anti-counterfeiting.
3:45 Speaker 02 Let's cut out illicit substances coming into the country from offshore. In effect, though, the bills don't do anything about the black market, or the gray market, or counterfeiting, or illicit substances. The bills do nothing to make patients safer. And in fact, the bills impose on state licensed compounding pharmacies standards that are very difficult for those pharmacies to meet. They basically impose manufacturer level standards. CGMP. Manufacturing practice standards on independent pharmacies that prepare one drug for one patient.
4:27 Speaker 02 The standards, though, for CGMP are for manufacturers of drugs that make millions of doses for millions of patients. And so many of the pharmacies aren't going to be able to adhere to the testing requirements. Those testing requirements, by the way, that have already been done at both the manufacturer and the wholesaler level and documented in a certificate of analysis. And so the result is going to be impede patient access to certain compounded therapies. Some of these bills have been very broad and affect all compounded therapies. Others have been fairly tailored, shall we say, to only restrict GLP-1 compounding. Or the Florida bill, for instance, would restrict compounding of weight loss drugs.
5:12 Speaker 02 And weight loss is not defined, so that's going to sweep in to those restrictions and requirements well more than just GLP-1s. So we have undertaken, APC has undertaken with our sister association, the Outsourcing Facilities Association, an effort to push back against this threat. It's called the Compounding Defense Initiative, and I'll be happy to say more about it.
5:34 Speaker 01 Okay. Let me, before we go any further, I just want to rattle off the list of states so that listeners can, you know, if they're in one of these states, they'll know it's going to affect them. So far, it's, there are bills, anti-compounding bills being introduced in Arizona, Colorado, Florida, Indiana, Mississippi, Virginia, Washington State, Georgia, and possibly Pennsylvania. When I look at this list, I see nothing in common with these states. They're geographically diverse, they're red, they're blue, they're all over the place. Why have drug makers chosen these states to introduce the bills?
6:12 Speaker 02 It's a great question, and we've been looking for some theme, some pattern, and there doesn't seem to be one. As you say, I mean, Virginia's a purple state. Florida is a red state. Mississippi's a red state. Colorado's a blue state. And so we don't think that that flavor of partisanship really has anything to do with it. At the end of the day, I think they have found traction in states where they found a chair or a vice chair of a committee of jurisdiction in that particular legislature who is willing to introduce the bill for them. And indeed, that's their strategy. We are finding that in most of these states where it's been introduced, the chairman of a committee, in a couple of instances, a vice chairman,
6:54 Speaker 02 has introduced the bill, which makes it frankly harder for members of the committee to push back against if they're opposed. Nobody likes to go up against a chairman. So that seems to be the only, the only pattern that we can discern.
7:08 Speaker 01 Okay. Now, obviously, I mean, to be a cynic here, the drug companies are doing this to protect their market share, make their shareholders...
7:18 Speaker 02 Do you think?
7:20 Speaker 01 I think a little bit. They're trying to make their shareholders happy. And obviously, they're not pitching it that way to legislators. You mentioned that they're saying there are issues with counterfeiting, there are issues with gray market drugs. Are those real issues? I mean, it's easy to say they're pitching bills to fight something that doesn't exist, but I mean, from what I understand, there is some problem with gray market and counterfeit drugs? But, you know, how big a problem is it really?
7:52 Speaker 02 Well, the counterfeit market and illicit substances purporting to be GLP-1s and a range of other drugs coming into this country is a seriously legitimate problem. And some crackdown on that is absolutely due. We need, we need, we need more enforcement. But that's not what these bills do. And I should assert, illicit substances coming into this country are not going to state licensed compounding pharmacies. I mean, a pharmacy that is sourcing... API from a non FDA registered inspected deemed CGMP compliant manufacturer will not
8:32 Speaker 02 have a pharmacy license for long because state boards of pharmacy come in with regularity once a year or so and inspect they're looking at those prescriptions and a pharmacy that's not sourcing appropriately would immediately be written up they could be fined they could lose their license it's a serious infraction and so as a business strategy that just didn't work for a state licensed pharmacy these substances coming into the country are going to illicit actors the national association of boards of pharmacy says that as as high as 90% of online pharmacies are bogus and it's those entities that are peddling these illicit substances purporting to be something that they may or may not be and patients who
9:16 Speaker 02 are getting those substances without a prescription that are getting advice and are you know a reddit chat room where somebody tells them they can buy a lyophilized powder and order it from overseas and then hop down to the Walgreens and get some distilled water and syringe and inject themselves well I mean that's a case of meningitis waiting to happen
9:36 Speaker 01 Wait, wait, wait, are you actually saying and I want I want you on the record for this are you actually saying that if I get medical advice and I buy some random weight loss drug off of a link on TikTok that I'm taking a risk here?
9:53 Speaker 02 You think? I'm sorry getting your healthcare advice from TikTok is probably not a good strategy for survival shall we say and so and so it's seriously I'm being glib but the the that is actually happening I mean you can go in those chat rooms and get advice for where you can get these substances that don't come from a state licensed pharmacy that are not from FDA registered manufacturers and wholesalers and so that needs to be addressed but that's not what these bills do these bills take state licensed pharmacies that operate under the US Food Drug and Cosmetic Act and FDA guidance And state pharmacy law and the standards of the U.S. pharmacopoeia, the compounding
10:37 Speaker 02 chapters, which are rigorous standards for preparing one drug for one patient and imposing on those pharmacies additional standards that they can't meet. And the interesting thing about both the drug maker's strategy and I respect state legislators greatly, I think they are serving their constituents, but I find it a bit frustrating that some of them are interested in introducing or voting for these bills and they've not reached out to the state board of pharmacy to ask, hey, hey, you regulators over this industry, is this a legitimate problem? Do we really need this overlay of new regulation on state licensed pharmacies?
11:20 Speaker 02 Generally speaking, that has not happened. And so drug makers are selling to these legislators a problem that doesn't exist with state licensed pharmacies.
11:31 Speaker 01 And then
11:32 Speaker 02 It's a serious threat.
11:33 Speaker 01 And then they're solving it or purporting to solve it with a sledgehammer.
11:38 Speaker 02 You got it. This is that this whole strategy is a blunt instrument. Now, now, look, I think if you want to have a conversation about opportunism in the GLP-1 compounding space, that's a conversation we can have. And we might find areas of, we would certainly find areas of disagreement, but we might find areas in which we agreed. These bills, not a one of them, and they're all very similar, by the way, there's a Novo version, there's a Lilly version, they're very similar, and yet, in the nine states where they've been introduced, not a one of them is exactly the same, but they, they,
12:20 Speaker 02 they all are sort of cut from the same cloth and they don't do anything to even address that problem. And so I think this is a sledgehammer where if anything's needed, it was a scalpel.
12:34 Speaker 01 So you mentioned you're fighting back through the compounding defense initiative, ABC and its partners. And so far, based on my notes, you've won legislative battles already, at least five of them, five different states. You've had the bills, you've been able to get the bills squashed either in committee or subcommittee.
12:59 Speaker 01 But here's a question to speculate. What if one of these bills passed? Pick any of the states that's got one. What would happen for patients? What would happen for pharmacists if the bill passed as Eli Lilly or Novo Nordisk has written? And as an aside, just the idea that drug companies are writing bills, and as I understand it, they actually are writing these bills and then giving them to state legislators and saying, hey, here's the bill. We'd like you to introduce that. I know that just kind of goes against civics 101 for me.
13:37 Speaker 02 Well, maybe maybe only because you're thinking that way only because it's a corporation, but that that happens all the time, entities. I mean, we we work with Congress and urge members of Congress to pass legislation that protects patient access to compounded drugs. What's interesting about this strategy by drug makers is is that it is so brazenly protectionist. They are carving out their GLP-1 drugs and putting extra restrictions on the compounding of the drugs. And so the practical effect, I mean, the drug makers will say all day long, oh, we're not we're not prohibiting compounding of GLP-1s. Well, in in in most of these instances, they're putting in place requirements that the pharmacies
14:22 Speaker 02 aren't going to be able to meet. And even those who might be able to meet those additional requirements beyond state license law, beyond beyond USP, are going to incur additional cost, which makes the ability of the patient to afford, they're going to have to raise the prices. And so the ability of the patient to afford the drug and and therefore access to drug is is at risk. In some of these, patient access will be cut off as a result of these bills if they were to pass. In other states, the access would would become much more difficult. And again, I can't say enough how brazen an approach this is. It is trying to, it's almost like regulatory capture. It's writing into law a protection for your product.
15:06 Speaker 01 So, okay, you've got, as we've said, nine, nine bills introduced. You've won a bunch of them. There are still several that are in various stages of the legislative process. What happens next? Are there more you see being introduced? Have you heard rumors of this? And what is the Compounding Defense Initiative planning next to, to deal with the issue?
15:31 Speaker 02 Well, it's, it's a great question. So we saw this coming back in the fall when we began to hear about the, the drug maker shopping the bills. We did not know at that point what the scope of the uptake would be. I mean, the fact that we don't have 50 states where these bills are introduced tells me that in many states, they couldn't find a drug maker who was willing to introduce this bad legislation.
15:54 Speaker 01 Whoops. Scott meant to say that they couldn't find lawmakers to introduce these bills, not drug makers.
16:01 Speaker 02 In the nine states where the bills have been introduced, we have been able to either have set aside or, or to kill the bills. And I mean, it's five of them, so you may have to help me, Andrew. Virginia was the first state where the bill was set aside. Two bills in Florida died in committee. Mississippi, committee voted to kill the bill. Arizona, and that's, as of this time we're recording, Arizona's the most recent one. And there was a tie vote in the committee of jurisdiction and on a tie vote, the bill died. So that one was a squeaker and, and worrisome. And then Washington state was just overwhelmingly put down. I think that may be five states.
16:46 Speaker 02 We still have bills pending in Indiana, Eli Lilly's home state. And the bill in Indiana is, right now, the bill that has made it the farthest. The Senate basically gutted the original bill and made some changes that would apply, would, would put med spas, and we need to talk about med spas, by the way, put med spas within the reach of state boards of pharmacy and then would incorporate sections 503A. and 503B of the Food Drug and Cosmetic Act into Indiana law. It went over to the House and recently the House has made further significant changes
17:28 Speaker 02 to the bill, most of which, this has only just happened in the past 24 hours. Most of those we think we can live with. We are still reviewing. We do have a bill in Colorado that has not yet had a hearing and we have a, my concern is that in some of these states, we have legislators that are believing the fantasy that the drug makers have sold them despite not, not, not hearing from boards of pharmacy about legitimate concerns. And so, you know, I'm a little, I'm a little concerned about Colorado and then Georgia is the most recent one and I, my, my suspicion is that we'll be fine in Georgia and the
18:11 Speaker 02 bill will not get, get, get, get out of the House there. We're hearing rumors of the bill to be introduced in Pennsylvania. It may be that by the time this episode airs, something will have been introduced there. It's not more states because they couldn't find anybody to introduce it. We have pulled together a coalition, the Outsourcing Facilities Association, that's the trade association that represents 503B outsourcing facilities, and us, and we represent both 503A and 503B. We are certainly raising money from our members to engage lobbyists in all of these states. We have been very fortunate in several of these states to be able to work, collaborate with the state pharmacy associations.
18:56 Speaker 02 And most of these state pharmacy associations have taken a position in opposition to the bill or have been integrally involved in helping improve the legislation. Indiana is a good, good example of that. Can't say enough good things about the Indiana Pharmacists Association and their work to, to improve the bill. Washington State Pharmacists Association, fantastic. Arizona. And so, we're, we're grateful to sort of have this clunky coalition of folks who are trying to tell legislators the truth about what's going on. I think our track record is pretty good. And I babbled on. Your real question was what happens next?
19:36 Speaker 02 We still have some states in which the legislative timeline is such that a bill could be introduced. So there may be a state where we're going to see a bill that we don't yet know about. But for most states, the deadline for introduction of new legislation has passed. And so we begin to look toward next year. We do, by the way, have to be vigilant in watching some of these bills because amendments can be made to other bills that might be judged germane late in session. And so even though we, you know, it looks like we put a bill down in Florida, it may be that somebody could attach the language of the bad legislation to another piece of legislation.
20:21 Speaker 02 And so we're having to keep watch for that. As we, as we move toward the summer, this is not a one and done. I do not believe drug makers are going to say, oh, well, we tried that in nine states, didn't work, or it didn't work the way we thought it would, we're, we're, we're out. They've got infinite resources. They've got more money than God, as my grandmother would say. And I believe we will see a return of the strategy next year, and they will have learned from some of the, learn some lessons from, from, from what's occurred this year. I think as an industry, we're going to have to be ready for that. And you will, you will see APC preparing for the fight to continue as we, as we go forward.
21:02 Speaker 01 Okay. We've been talking about mostly GLP-1, weight loss diabetes drugs. And that's what most of the legislation seems to be targeting, although in some cases, it's a much broader target of compounding in general. But the focus seems to be on GLP-1 drugs. So I'd like to, to transition over to the federal level because of that statement that I mentioned earlier from FDA Commissioner McCary.
21:37 Speaker 01 He's talking in a statement, he alluded to limiting or even prohibiting compounding with the active ingredient, the API, that's in these GLP-1 weight loss and diabetes drugs, semaglutide, tirzepatide, notably. Right now, and correct me if I'm wrong, as long as a prescriber says that a patient needs a compounded version of semaglutide or tirzepatide, it's perfectly legal for a compounding pharmacist to use those APIs to make formulations. It's up to the prescriber believes it, then it's legal to do this.
22:16 Speaker 01 So can the FDA just snap its fingers and restrict one or two APIs that are already legal to compound with?
22:25 Speaker 02 Okay, there's a lot wrapped up there. So first of all, I'm going to correct you.
22:29 Speaker 01 Okay.
22:30 Speaker 02 Federal law allows prescribing or dispensing of a compounded drug when an FDA-approved drug is in shortage. FDA guidance allows compounding pharmacies to make what FDA calls essentially a copy of the FDA-approved drug. That's when the drug's in shortage. Semaglutide, tirzepatide, FDA has deemed them out of shortage now, and so that does not apply. There should be no making of essentially copies of FDA-approved GLP-1 drugs right now. On the other hand, the other instance in which compounding is authorized is when a prescriber, in her judgment, determines that a specific formulation for an individual
23:12 Speaker 02 patient is needed, and there's not an FDA-approved drug corollary to that specific formulation. She needs a different dosage form, or dosage strength, or combination of drugs for that individual patient. And so, in that regard, yes, what you said is true. The criteria for substances that can be used in compounding, there's a three-fold criteria, it's one of these three. It has to be a component of an FDA-approved drug, well, semaglutide, tirzepatide are components of FDA-approved drugs. Or it needs to have a national formulary or USP monograph, or it needs to be on this curated list that FDA keeps.
23:57 Speaker 02 It has a slightly fancier title, but it's the 503A bulks list. And so in the environment that they're in right now, prescriber judges that a custom formulation of semaglutide or terzepatide is appropriate for an individual patient. She can write a prescription for that compounded drug for that patient. Again, compounders can only use active ingredient that comes, and this is in the law as well, has to come from FDA-registered facility. And generally, one would presume that that is FDA-inspected and deemed to be CGMP compliant. And indeed, FDA, back in the fall, created a green list
24:39 Speaker 02 of GLP-1 manufacturers that it deemed to be CGMP compliant. Some of them had been inspected. They were all FDA-registered, but FDA was, by putting them on the green list, deeming them to meet the criteria for compounding. And so as long as a pharmacy is acquiring the API from one of those, by our reading of the law, they should be able to do that. And so what was unusual about Dr. McCary's statement was the stridency of it. I think the timing was interesting. It came on the heels of what I would characterize as a provocative move by a telehealth platform.
25:21 Speaker 02 And it makes us wonder exactly what the commissioner has in mind. I don't know that, just across the board, FDA has the ability to prohibit the use of an active pharmaceutical ingredient when it is an ingredient that is authorized, that meets the criteria in the Food, Drug and Cosmetic Act, and FDA has already deemed that it's safe for use in an FDA-approved drug. So are they talking about import restrictions on certain manufacturers?
25:56 Speaker 02 Well, that will be interesting if they've released the green list back in the late summer or fall, and now they're going to put import restrictions on API from some of those manufacturers that they had deemed in compliance back in the fall. That seems to be an odd thing to do. Certainly, they could bow to the demands of the drug makers and move to add the GLP-1 API to the demonstrably difficult to compound list. I would argue that the drug makers' arguments for doing that are remarkably flimsy, but it doesn't mean FDA could not
26:40 Speaker 02 do it. Even so, adding drugs to the demonstrably difficult to compound list, a list, by the way, which is not finalized, it technically doesn't exist because of criteria, has not been finalized by the agency yet. But let's say they did that. You're going to have to go through a protracted notice and comment rulemaking period to do that. So if that's the course they take, I kind of hope they don't. I think the science, as I've said, is flimsy. It's going to take a while to do that. Notice and comment rulemaking is not a quick process. And so, all of that is pure speculation. If there are other tools in their books for, or in their bag of tricks, I guess, for restricting GLP-1 compounding,
27:24 Speaker 02 I'm not quite sure what they are. The other thing that should be noted, though, the commissioner did say that they intend to restrict compounding with GLP-1 API. His statements, and multiple statements, not just the one that was released on the 6th, but a tweet on the 5th.
29:42 Speaker 01 But saying that you can't say that you're using the same active ingredient. I mean, I look at, at, you know, medication all the time and I'll, I'll see, it'll say, you know, acetaminophen, the same active ingredient as Tylenol, but it's a, it's a generic version. There's no problem there.
30:01 Speaker 02 Well, and it may, I mean, I'm speculating, I'm not a lawyer. It may be the use of the trademark term, you know, same active ingredient as in Wegovy. Maybe that's the concern, that it's so specific to the, the, the, the commercial name of the drug. I, I don't know, but we're, we're, we're waiting for the other shoe to drop. We're waiting to see what the agency will actually do in, in, in, in this regard. So.
30:28 Speaker 01 Well, let's, let's go take a step back and look at the, the bigger picture with those statements. Why would FDA Commissioner McCurry say stuff like this? Why, I mean, wouldn't the FDA want patients to get the drugs in the formulations that their prescribers say is appropriate? Wouldn't the FDA want patients to get the, the right drugs, whether it comes from, it comes with an Eli Lilly brand on it, or it comes from a state licensed compounding pharmacy? Why is the FDA doing this? Or threatening to do this?
31:07 Speaker 02 Yeah. Pure speculation, but again, some of it came, had to do with timing. On February 5th, you had a telehealth platform make a remarkably provocative marketing move. And I would view Dr. McCurry's response as a direct response to that. I would suspect that FDA heard immediately from the drug makers and were feeling pressure to, to, to respond to this move by the telehealth platform. And this is, this is how it, this is how it came out.
31:46 Speaker 02 I, I, I don't know beyond that, but, but it, it, it has to be tied in one way or the other to the, the, the, the action by the telehealth platform. I just don't see any other reason the agency would sort of arbitrarily make that sort of, uh, uh, announcement.
32:03 Speaker 01 All right. So lot, lot of big and related issues going on here at the state level with bills that would restrict compounding, specifically some, in some cases of GLP-1 drugs. You've got the federal level with insinuations, threats, however you want to describe it, against compounding pharmacies for their marketing and for dispensing legally, at this point legally dispensing these drugs. First of all, thank you for, for taking the time. As I said before, you are, you're up to your chin at least in, in dealing with
32:42 Speaker 01 this. So for the listeners, where can people get more information? The state level issues, the FDA issues, is there an easy place for them to get the updates on what's happening?
32:54 Speaker 02 Yeah. Well, the best thing you can do is join APC. We would love to have more in our community of compounding pharmacies and compounding stakeholders. On the multi-state legislative threat, compounding.com is your best resource. We have set up individual pages for the landing pages, I guess, for the states where this legislation has been introduced. You should be able to find a copy of the bill, our analysis of the bill. In some of these states, we've, we've issued calls to action for residents of the state, prescribers in the state, to reach out to members of their legislature. So there's a lot there
33:36 Speaker 02 at compounding.com. In terms of FDA statement, I mean, again, if you're, if you're a member of APC, you get our weekly newsletter, where we're speaking and addressing and this issue and sharing what we know weekly in that venue. You can also follow us on LinkedIn, Facebook, and Instagram, and we should be able to keep you in the know there as well.
34:01 Speaker 01 All right. Thank you. That was again Scott Bruner. He is the CEO of the Alliance for Pharmacy Compounding. And before we play the outro music, if you are a compounding pharmacist or a technician, or if you prescribe compounding meds, as Scott pointed out, APC is there for you. It's helping you. It's helping your patients. So not to go through everything APC does, but certainly in terms of keeping up with the latest regulations and the threats to to compounding, APC is the biggest, the loudest trade organization, trade association for compounding. So if you're not a member, you should consider becoming one. APC is working
34:42 Speaker 01 for you. You can find out more at A4PC.org. That's A, the number four, PC.org. And as Scott mentioned, on compounding.com. And now we can play that outro music. Thanks, everybody for listening.
Previous LTC Pharmacy at a Crossroads: Maximum Fair Price, the IRA, and What DC Means for 2026 and Beyond Next PBM Reform Update from CPhA | PBM Reform with APCI Page updated November 14, 2026 · transcript and summary are machine-generated